|1.||Kietzmann, Manfred: 5 articles (04/2007 - 06/2002)|
|2.||Bäumer, Wolfgang: 4 articles (04/2007 - 06/2002)|
|3.||Murdoch, R D: 4 articles (01/2003 - 06/2001)|
|4.||Kelly, J: 4 articles (01/2003 - 06/2001)|
|5.||Rennard, Stephen I: 3 articles (01/2006 - 10/2002)|
|6.||Leung, Bonnie: 2 articles (01/2013 - 01/2011)|
|7.||Chong, Jimmy: 2 articles (01/2013 - 01/2011)|
|8.||Poole, Phillippa: 2 articles (01/2013 - 01/2011)|
|9.||Iwata, Masahiro: 2 articles (01/2012 - 06/2011)|
|10.||Shimizu, Yasuaki: 2 articles (01/2012 - 06/2011)|
|1.||Chronic Obstructive Pulmonary Disease (COPD)
07/01/2001 - "Cilomilast has been evaluated in Phase I, Phase II and Phase III trials and dose-response experiments have demonstrated a clinically significant increase in lung function and a perceived improvement in quality of life in patients with COPD. "
05/01/2005 - "Significant reduction was observed in subepithelial neutrophil, CD68(+) monocyte and CD8(+) lymphocyte densities in bronchial biopsies of COPD patients following administration of cilomilast for 12 weeks. "
10/01/2006 - "Given its unique mechanism of action and improved adverse effect profile compared with previous agents, cilomilast may have a promising role for the management of COPD."
10/01/2006 - "To date, 4 clinical trials have evaluated the efficacy of cilomilast and demonstrated improvement in lung function (forced expiratory volume in 1 second) and quality of life and reduction in the occurrence of COPD exacerbations compared with placebo. "
01/01/2006 - "This study evaluated the efficacy of cilomilast, a selective phosphodiesterase (PDE) 4 inhibitor, in the treatment of COPD. "
|2.||Asthma (Bronchial Asthma)
12/01/1998 - "These results, coupled with the broad anti-inflammatory activity of SB 207499 previously described (Barnett et al., 1998), suggest that SB 207499 will be useful in the treatment of asthma and other inflammatory disorders."
07/01/2001 - "Trials of cilomilast in asthma have been less impressive although a trend towards improved lung function has been reported. "
07/01/2001 - "Cilomilast (Ariflo, SB-207499) is an orally-active, second generation phosphodiesterase (PDE) inhibitor that may be effective in the treatment of asthma and chronic obstructive pulmonary disease (COPD). "
01/01/2002 - "Indeed, cilomilast is showing good therapeutic effects in clinical trials for asthma and COPD and represents the most advanced selective PDE4 inhibitor for any indication. "
09/01/1999 - "Ariflo (SB-207499) is a phosphodiesterase (PDE)4 inhibitor under development by SmithKline Beecham and in phase III and II clinical trials as a potential treatment for chronic obstructive pulmonary disease (COPD) and asthma, respectively . "
12/01/2006 - "We speculated that cilomilast might reduce mediators of airway inflammation and angiogenesis from the airway epithelium, supporting a potential value in the treatment of BOS. "
01/01/2006 - "Cilomilast exhibits favourable and predictable pharmacokinetics, has few clinically relevant drug-drug interactions and has demonstrated effects on measures of inflammation of potential benefit in the treatment of COPD. "
01/01/2007 - "This study investigated the effect of prednisolone and of the PDE-4 inhibitor cilomilast on the LPS-induced acute inflammation. "
01/01/2007 - "In healthy subjects, while the LPS-induced airways' inflammation was not modified either by oral prednisolone or by PDE-4 inhibitor cilomilast (at actual dosage), the LPS-induced acute phase of blood inflammation was reduced by prednisolone."
01/01/2007 - "Neither prednisolone nor cilomilast had protective effect on the LPS-induced airways' inflammation. "
04/01/2006 - "Nausea, presumably of central origin, is the principal adverse reaction seen in healthy subjects taking cilomilast. "
01/01/2006 - "Nausea was the principal adverse reaction seen in healthy subjects taking cilomilast, but this was reduced by administration with food or by use of simple dose-escalation regimens. "
04/01/2006 - "In both studies, the most frequently reported AEs with cilomilast use were nausea (8/18 in study 1 and 3/16 in study 2) and headache (8/18 in study 1 and 6/16 in study 2); however, these were generally of mild to moderate intensity. "
01/08/2005 - "Roflumilast has a better safety and tolerability profile than cilomilast, with the main adverse effects being nausea, diarrhoea, and abdominal pain. "
06/01/2005 - "The initially detected side effects, mainly nausea and emesis, appear at least partially overcome by the 'second generation' PDE4 inhibitors, some of which like roflumilast and cilomilast are in the later stages of clinical development for treatment of chronic obstructive pulmonary disease. "
01/01/2003 - "cilomilast), inhibitors of tumour necrosis factor-alpha (e.g. "
07/01/2003 - "The ability of cilomilast to inhibit the release of neutrophil chemoattractants such as tumour necrosis factor (TNF)-alpha, interleukin (IL)-8, and granulocyte-macrophage colony stimulating factor (GM-CSF) by bronchial epithelial cells and sputum cells isolated from 10 patients with COPD, 14 normal controls, and 10 smokers was investigated. "
11/01/2006 - "The effects of cilomilast+/-salmeterol on the following were determined: 1) surface CD11b expression; 2) adhesion; 3) intracellular cyclic adenosine monophosphate (cAMP) concentration; and 4) extracellular signal-regulated kinase (ERK)-1/2-mediated group IVA-phospholipase A(2) (gIVA-PLA(2)) phosphorylation caused by leukotriene (LT)B(4) or tumour necrosis factor (TNF)-alpha activation. "
01/01/2012 - "In this study, we compared the ability of the phosphodiesterase IV (PDEIV) inhibitor Cilomilast, the steroid Budesonide, and the p38 mitogen activated protein kinase inhibitor BIRB-796 to inhibit tumour necrosis factor alpha (TNFα) and interleukin 6 (IL-6) releases from AMs isolated from COPD lung transplant tissue. "
|2.||Phosphodiesterase 4 Inhibitors
|6.||Matrix Metalloproteinase 12
|8.||Type 4 Cyclic Nucleotide Phosphodiesterases
|10.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|2.||Heterologous Transplantation (Xenotransplantation)